기업 정보 불러오는 중
Just reported
Q3 2026 results
From Pfizer's results release of 2026년 11월 3일; its quarterly report has since been filed.
Revenue
Actual
US$16.58B
-0.4% y/y
+10% q/qGuided
—
No guide given
EPS, GAAP
Actual
US$0.56
-9.7% y/y
Guided
—
No guide given
Company outlook
Full year 2026
- EPS, adjustedUS$2.95 – US$3.05Raised +3.4%
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Pfizer is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The themes it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And CompanyUS$1.35TA+
JNJJohnson & JohnsonUS$674.9BA+
MRKMerck & Co., Inc.US$362.9BA
NVSNovartis AGUS$306BA
AMGNAmgen Inc.US$253.2BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026년 10월 21일CBGraded C, now B
MCKMckesson Corporation2026년 11월 4일BAGraded B, now A
CVSCVS Health Corp2026년 11월 4일BAGraded B, now A
EWEdwards Lifesciences Corporation2026년 11월 4일BAGraded B, now A
BIIBBiogen Inc.2026년 10월 28일BAGraded B, now A
어떻게 돈을 버는가
- Sales of its medicines and vaccines95%
- Royalties3%
- Contract manufacturing and drug ingredients2%
- Research and development services0%
매출 비중은 year ended December 31, 2025, high confidence 기준 추정치이며, 제출된 보고서의 수치가 아닙니다.
경쟁 상대
무엇을 파는가6
Eliquis
A prescription medicine that helps prevent blood clots and strokes in certain patients. Pfizer shares its development and commercial profits with Bristol Myers Squibb.
Pfizer vaccine portfolio
Vaccines include the Prevnar family for pneumococcal disease, Comirnaty to help prevent coronavirus disease, and Abrysvo for respiratory syncytial virus.
Paxlovid
A prescription medicine used to treat coronavirus disease.
3개 더 보기
Oncology medicines
Cancer medicines include Ibrance for breast cancer, Padcev for bladder cancer, and Xtandi for prostate cancer.
Nurtec ODT and Vydura
Migraine medicines. ODT means orally disintegrating tablet.
Vyndaqel family
Medicines for transthyretin amyloidosis, a disease in which an abnormal protein builds up in the body and can damage the heart or nerves.
누가 사는가4
- Wholesalers, which buy prescription medicines for resale to pharmacies, hospitals and other providers.
- Retailers, pharmacies, hospitals and clinics, which buy medicines directly for patients or for use in care.
- Government agencies and health institutions, which buy vaccines and medicines through contracts or purchasing programs.
- Insurers and pharmacy benefit managers, which negotiate rebates and decide which medicines are covered or preferred on their drug lists.
무엇에 기대고 있고, 무엇이 무너뜨릴 수 있는가
사업이 기대고 있는 것
- 1Revenue depends on continued sales of major medicines and vaccines; generic competition after patent or regulatory exclusivity ends can reduce sales.
- 2Some important products rely on partnerships: Pfizer shares profits from Comirnaty with BioNTech and from Eliquis with Bristol Myers Squibb, among other collaborations.
- 3Sales depend on wholesalers and other distribution channels, and on insurers and pharmacy benefit managers covering products and setting their place on medicine lists.
- 4Pfizer buys raw materials from suppliers worldwide and relies on manufacturing sites and supply chains to make and deliver products.
잘못될 수 있는 일
- 1When patent protection or regulatory exclusivity ends, generic or biosimilar manufacturers can sell lower-priced alternatives. Pfizer says competition can quickly reduce sales of affected products.
- 2Government price-setting, required rebates and insurer demands can lower the prices Pfizer receives or limit access to its medicines. The Medicare price-negotiation program now sets a price Pfizer must offer for Eliquis.
- 3Drug development and regulatory approval can fail or change. Pfizer reported that a late-stage study of its investigational cancer medicine sigvotatug vedotin did not meet its main survival goal, and that it withdrew Oxbryta from the United States market after reviewing clinical and registry data.
Pfizer Inc. 소개
Pfizer discovers, tests, manufactures, markets and sells medicines and vaccines around the world. Its products address conditions including cancer, heart and blood-vessel diseases, migraine, infections, immune disorders and rare diseases. It also makes medicines and drug ingredients for other companies and is winding down a research-services business for biotechnology companies.
- 본사
- New York City, New York
- 설립
- 1849 (company founded, high confidence)
- 임직원 수
- 75,000 (December 31, 2025, high confidence)
- 상장 시장
- NYSE
- 회계연도 종료
- December 31
Pfizer Inc.이(가) 미국 증권거래위원회(SEC)에 직접 제출한 공시로 만들었습니다. 수치는 보고된 그대로이며, 주당 이력은 오늘의 주식 수 기준으로 재계산했습니다. 이것은 사업을 설명하는 자료입니다. 투자 자문이 아니며 어떤 매수나 매도도 권유하지 않습니다.
